Please login to the form below

Not currently logged in
Email:
Password:

cell cancer

This page shows the latest cell cancer news and features for those working in and with pharma, biotech and healthcare.

Hemlibra off to a flyer as Roche raises 2019 forecasts

Hemlibra off to a flyer as Roche raises 2019 forecasts

However, new drugs including Ocrevus (ocrelizumab) for multiple sclerosis, cancer immunotherapy Tecentriq (atezolizumab) and new haemophilia drug Hemlibra (emicizumab) acted as a buffer. ... With Roche’s pipeline set to deliver approvals some more

Latest news

More from news
Approximately 1 fully matching, plus 685 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    patient.”. Althoff cites Novartis’ Kymriah (tisagenlecleucel), a blood cancer cell therapy approved in Europe and the US last year, as an example of the differing manufacturing costs. ... As a result, Lonza’s efforts to reduce cell and gene therapy

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of

  • China’s clinical trial shake-up China’s clinical trial shake-up

    For example, around 40% of new lung cancer diagnoses worldwide are in China. ... Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

  • Is China ready for a pharmaceutical gold rush?

    Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June. ... The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    Cancers by their very nature are unique. The huge range of potential causes of the abnormal cell division that characterises cancer mean that every tumour is different. ... Drug development is outpacing our capacity to develop biomarkers due to the

More from intelligence
Approximately 0 fully matching, plus 38 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics